Effect of initial ziprasidone dose on length of therapy in schizophrenia

Schizophrenia Research

Volumn 83, Issue 2-3, 2006, Pages 285-292

  Joyce, Amie T ^a   Harrison, David J ^b   Loebel, Antony D ^b   Carter, Chureen T ^a   Ollendorf, Daniel A ^a  

^a PharMetrics Inc   (United States)

^b PFIZER INC   (United States)

Author keywords

Antipsychotics; Pharmacotherapy; Schizophrenic disorders; User compliance; Ziprasidone

Indexed keywords

NEUROLEPTIC AGENT; ZIPRASIDONE;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; RISK; SCHIZOPHRENIA; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33645877414     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.01.009     Document Type: Article

References (24)

1. Brown C.S., Markowitz J.S., Moore T.R., and Parker N.G. Atypical antipsychotics. Part II: adverse effects, drug interactions, and costs. Ann. Pharmacother. 33 2 (1999) 210-217 (Feb)
2. Cook R.J., and Sackett D.L. The number needed to treat: a clinically useful measure of treatment effect. BMJ 310 6977 (1995) 452-454 (Feb 18)
3. Consumer Health Information Corporation Patient Compliance Database Statistics (2004). http://www.consumer-health.com/services/dtc_strategies.htm Accessed December 29, 2005
4. Daniel D.G., Zimbroff D.L., Potkin S.G., Reeves K.R., Harrigan E.P., Lakshminarayanan M., and Ziprasidone Study Group. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 20 5 (1999) 491-505
5. Dickerson F.B., Pater A., and Origoni A.E. Health behaviors and health status of older women with schizophrenia. Psychiatr. Serv. 53 7 (2002) 882-884 (Jul)
6. Fleishhacker W.W. Evolution of antipsychotic therapy: a mechanism based evaluation. J. Clin. Psychiatry 64 11 (2003) 1379-1390 (Nov)
7. Grant R.W., O'Leary K.M., Weilburg J.B., Singer D.E., and Meigs J.B. Impact of concurrent medication use on statin adherence and refill persistence. Arch. Intern. Med. 164 21 (2004) 2343-2348 (Nov)
8. Gilmer T.P., Dolder C.R., Lacro J.P., Folsom D.P., Lindamer L., Garcia P., and Jeste D.V. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry 161 4 (2004) 692-699 (Apr)
9. Hall L.L., Graf A.C., Fitzpatrick M.J., Lane T., and Birkel R.C. Shattered lives: results of a national survey of NAMI members living with mental illnesses and their families. Treatment/Recovery Information and Advocacy Database (TRIAD) Report (2003), National Alliance on Mental Illness, Arlington, VA
10. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., and Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 63 10 (2002) 892-909 (Oct)
11. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Lebowitz B.D., Severe J., Hsiao J.K., and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 12 (2005) 1209-1223
12. Keck Jr. P., Buffenstein A., Ferguson J., Feighner J., Jaffe W., Harrigan E.P., and Morrissey M.R. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140 2 (1998) 173-184
13. Keck Jr. P.E., Reeves K.R., Harrigan E.P., and Ziprasidone Study Group. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J. Clin. Psychopharmacol. 21 1 (2001) 27-35
14. Maixner S.M., Mellow A.M., and Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J. Clin. Psychiatry 60 Suppl 8 (1999) 29-41
15. Mamo D., Kapur S., Shammi C.M., Papatheodorou G., Mann S., Therrien F., and Remington G. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am. J. Psychiatry 161 5 (2004) 818-825 (May)
16. Masand P.S., Nemeroff C.B., Lieberman J.A., Weiden P.J., Harvey P.D., Newcomer J.W., Schatzberg A.F., Kilts C.D., and Daniel D.G. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr. 10 11 Suppl 17 (2005) 1-19 (Nov)
17. Menzin J., Boulanger L., Friedman M., Mackell J., and Lloyd J.R. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr. Serv. 54 5 (2003) 719-723 (May)
18. Mullins C.D., Shaya F.T., Magno Zito J., Obeidat N., Naradzay J., and Harrison D.J. Effect of initial ziprasidone dose on treatment persistence in schizophrenia. Schizophr. Res. 83 (2006) 277-284 10.1016/j.schres.2006.01.013 (this issue)
19. Murray S., Siu C.O., and Romano S.J. Optimal dosing of oral ziprasidone: clinical trial data. Presented at the 54th Annual Meeting of the Institute on Psychiatric Services; October 29-November 2, 2003; Boston, MA (2003)
20. Murray S., Mandel F.S., and Loebel A. Optimal initial dosing of ziprasidone: clinical trial data. Presented at the 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY (2004)
21. Perkins D.O. Adherence to antipsychotic medication. J. Clin. Psychiatry 60 suppl 21 (1999) 25-30
22. Ritsner M., Gibel A., Perelroyzen G., Kurs R., Jabarin M., and Ratner Y. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J. Clin. Psychopharmacol. 24 6 (2004) 582-591 (Dec)
23. Simpson G.M., Glick I.D., Weiden P.J., Romano S.J., and Siu C.O. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am. J. Psychiatry 161 10 (2004) 1837-1847 (Oct)
24. Vanelli M., Burstein P., and Cramer J. Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain. Psychiatr. Serv. 52 9 (2001) 1248-1250 (Sep)